Health  Vol.9 No.10 , September 2017
Clinical Study: Lotion Containing Propolis Special Extract GH 2002 0.5% vs. Placebo as On-Top Treatment of Herpes Zoster
Abstract: Background: The aim of the clinical trial was to establish the contribution of propolis special extract GH 2002 as constituent of a lotion for the supportive treatment of Herpes zoster. Methods: 60 patients with diagnosed Herpes zoster were either treated with a propolis containing (n = 33) or an identical, but propolis-free lotion (n = 27) for 28 days, as an add-on therapy to oral antiviral treatment with aciclovir. Study parameters were the assessment of pain on a visual analogue scale, the assessment of the formation of new vesicles, and the safety of application of the preparation. Results: Improvement of pain was significantly better and quicker in the propolis lotion group (p < 0.001 at all visits). On day 3/4, the reduction of pain versus baseline was 54% versus 20% reduction in favour of propolis lotion. On day 14 the results were 80% versus 42% pain reduction. Healing of lesions was significantly quicker with the propolis-containing lotion: at visit 3 on day 7, 21% versus none of the patients showed a closed skin with or without crusting. After 14 days, the comparison showed 57.6% versus 25.9%. At least 50% of propolis-treated patients were lesion-free on day 14, versus day 28 in the control group (p = 0.013). The formation of new vesicles was also significantly suppressed. On day 3/4 the number of newly formed vesicles was 15 versus 25, on day seven the number of new vesicles was 4 versus 14 (p < 0.001). The advantage of propolis lotion was confirmed through the global assessment of efficacy by the physician, with 75.8 versus 33.3% “good” to “excellent” ratings already on day 3/4, 90.9 vs. 44.4% on day 7, and 100 vs. 74.1% on day 28 (p < 0.001). Skin tolerability was excellent, no allergic reactions, skin irritations or other adverse events were observed. Conclusion: The observations clinically confirm antiviral and anti-inflammatory effects of propolis special extract GH 2002 and at the same time demonstrate the benefits of the topical add-on to the systemic antiviral therapy of Herpes zoster.
Cite this paper: Tomanova, D. , Holcova, S. and Hladíková, M. (2017) Clinical Study: Lotion Containing Propolis Special Extract GH 2002 0.5% vs. Placebo as On-Top Treatment of Herpes Zoster. Health, 9, 1337-1347. doi: 10.4236/health.2017.910097.

[1]   Kempf, W. and Lautenschläger, S. (2001) Infektionen mit dem Varizella Zoster Virus. Hautarzt, 52, 359-376.

[2]   Gross, G. and Doerr, H.W. (2003) Herpes Zoster Guidelines of the German Dermatological Society. Journal of Clinical Virology, 27, 308-309.

[3]   Gross, G., Schofer, H., Wassilew, S., Friese, K., Timm, A., Guthoff, R., Pau, H.W., Malin, J.P., Wutzler, P. and Doerr, H.W. (2003) Herpes Zoster Guideline of the German Dermatology Society (DDG). Journal of Clinical Virology, 26, 277-293.

[4]   Tyring, S., Belanger, R., Bezwoda, W., Ljungman, P., Boon, R. and Saltzman, R.L. (2001) A Randomized, Double-Blind Trial of Famciclovir versus Acyclovir for the Treatment of Localized Dermatomal Herpes Zoster in Immunocompromised Patients. Cancer Investigation, 19, 13-22.

[5]   Gopal, M.G., Sharath, S., Kumar, B.C., Nandini, A.S. and Namrata, C.M. (2013) A Comparative Study to Evaluate the Efficacy and Safety of Acyclovir and Famciclovir in the Management of Herpes Zoster. Journal of Clinical and Diagnostic Research, 7, 2904-2907.

[6]   Gross, G. (2003) Zoster und Zosterschmerzen. Journal der Deutschen Dermatologischen Gesellschaft, 1, 398-407.

[7]   Wassilew, S. (1984) Management of Pain in Herpes Zoster. Seminars in Dermatology, 3, 116-119.

[8]   Riopelle, J., Lopez-Anaya, A., Cork, R.C., Heitler, D., Eyrich, J., Dunston, A., Riopelle, A.J., Johnson, W., Ragan, A. and Naraghi, M. (1994) Treatment of the Cutaneous Pain of Acute Herpes Zoster with 9% Lidocaine (Base) in Petrolatum/Paraffin Ointment. Journal of the American Academy of Dermatology, 30, 757-767.

[9]   Holcová, S. and Hladiková, M. (2015) Local Treatment—Accompanying Care for Herpes Zoster with an Active Substance-Containing Lotion (Propolis Special Extract GH 2002). The Journal of Pharmacology and Experimental Therapeutics, 24, 3-7.

[10]   Walgrave, S.E., Warshaw, E.M. and Glesne, L.A. (2005) Allergic Contact Dermatitis from Propolis. Dermatitis, 16, 209-215.

[11]   Holcová, S. and Hladiková, M. (2011) Efficacy and Tolerability of Propolis Special Extract GH 2002 as a Lip Balm against Herpes Labialis: A Randomized, Double-Blind Three-Arm Dose Finding Study. Health, 3, 49-56.

[12]   Holcová, S. and Hladiková, M. (2012) Inhibierung der Entwicklung von Lippenbläschen durch frühzeitige Anwendung eines pflegenden Lippenbalsams mit dem Wirkstoff Propolis Spezialextrakt GH 2002 im Vergleich mit Aciclovircreme 5%. Kosmetische Medizin, 33, 100-104.

[13]   Schnitzler, P., Neuner, A., Nolkemper, S., Zundel, C., Nowack, H. and Sensch, K.H. (2010) Antiviral Activity and Mode of Action of Propolis Extracts and Selected Compounds. Phytotherapy Research, 24, S20-S28.

[14]   Nolkemper, S., Reichling, J., Sensch, K.H. and Schnitzler, P. (2010) Mechanism of Herpes Simplex virus Type 2 Suppression by Propolis Extracts. Phytomedicine, 17, 132-138.

[15]   Astani, A., Zimmermann, S., Hassan, E., Reichling, J., Sensch, K.H. and Schnitzler, P. (2013) Antimicrobial Activity of Propolis Special Extract GH 2002 against Multidrug-Resistant Clinical Isolates. Pharmazie, 68, 695-701.